Bionano Genomics Appoints Dr. Keith Gligorich, Seasoned Leader in CLIA-Certified CAP-Accredited Lab Operations, as VP Operations for Bionano Laboratories
November 29 2021 - 8:00AM
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping
(OGM) solutions on the Saphyr® system and provider of the leading
software for genomic data visualization, interpretation and
reporting, today announced that it has appointed Keith Gligorich,
PhD, MB(ASCP)cm to the role of VP Operations for Bionano
Laboratories. Keith was most recently with Guarant Health where he
led the build-out of Guardant’s CLIA-certified, CAP-accredited
laboratory for blood-based early cancer detection testing. He has
over a decade of experience in molecular diagnostic test
development and laboratory operations. Prior to joining Guardant
Health, Keith held leadership roles at ARUP Laboratories, Navican
Genomics and Cradle Genomics. Keith holds a PhD in organic
chemistry from the University of Utah.
“We are delighted to have Keith on board. We believe he is an
expert when it comes to CLIA labs and lab developed tests (LDTs)
operating at the forefront of science and technology,” commented
Dr. Alka Chaubey, chief medical officer of Bionano. “We look
forward to Keith leading the planned expansion of our offering to
include services and LDTs under CLIA-certification and
CAP-accreditation within Bionano Laboratories.”
Bionano Laboratories is Bionano’s strategic services offering
that provides researchers with access to OGM data to enable them to
incorporate OGM into their workflow for clinical and discovery
research. Designed to drive and potentially accelerate Saphyr
adoption around the world, Bionano Laboratories gives prospective
customers access to proof of concept data and rapid demonstrations
of the capabilities of OGM with Saphyr. Bionano began
obtaining CLIA certification and CAP accreditation for the San
Diego-based Bionao Laboratories in 2021 and plans to expand the
scope of services it offers to include laboratory developed tests
(LDTs) based on OGM. The menu of OGM-based LDTs is expected to
include tests for genetic diseases such as fascioscapulohumeral
muscular dystrophy (FSHD) and tests for hematologic malignancies
such as acute myeloid leukemia (AML) or acute lymphocytic leukemia
(ALL). This initial menu is intended to allow Bionano to work with
third party payors, such as health insurance companies, to develop
pathways for coding, coverage and reimbursement of LDTs based on
OGM.
“We believe Keith joining us from Guardant Health is a strong
indication of our exciting trajectory and demonstrates how
accomplished leaders can align with our purpose of elevating the
health and wellness of all people,” said Erik Holmlin, PhD,
president and chief executive officer of Bionano. “Keith brings
deep experience which can help us drive our anticipated menu
expansion and plans to incorporate the variant reporting software,
NxClinical™ from BioDiscovery, to create comprehensive workflows
that integrate next-generation sequencing (NGS) and OGM in a single
view. Chromosomal microarrays (CMA) are also expected to be part of
the data integration as they represent standard of care in genetic
testing under current national and international medical guidelines
such as those from the American College of Medical Genetics and
Genomics (ACMG). As we work to drive inclusion of OGM into the
standard of care as an alternative to traditional methods, the data
integration within NxClinical is expected to provide seamless
transitions for NxClinical users running the software for their CMA
and NGS to adopt and use OGM.”
About Bionano Genomics
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
Through its BioDiscovery business, the Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. For more
information, visit www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the Dr. Gligorich's
anticipated contributions to the execution of our strategy and
product development objectives, including with respect to menu
expansion and development of comprehensive workflows through the
incorporation of NxClinical and integration of NGS and OGM into a
single workflow; our expectations regarding the development of
OGM-baed LDTs; and our ability to execute on our business strategy.
Each of these forward-looking statements involves risks and
uncertainties. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of the COVID-19
pandemic on our business and the global economy; general market
conditions; changes in the competitive landscape and the
introduction of competitive products; our hiring efforts may not
achieve the anticipated results; approval processes required by
third party payors and overall challenges with obtaining any
related regulatory approvals; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of our technologies; the loss of key
members of management and our commercial team; and the risks and
uncertainties associated with our business and financial
condition in general, including the risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including, without limitation, our Annual Report on
Form 10-K for the year ended December 31, 2020 and in other filings
subsequently made by us with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made and are
based on management’s assumptions and estimates as of such date. We
do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of the receipt of
new information, the occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics,
Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024